Financial Performance - Revenue for the year ended December 31, 2023, was HKD 484.7 million, an increase of approximately 10.0% from HKD 440.3 million in 2022[15]. - Gross profit for 2023 was HKD 392.8 million, resulting in a gross margin of 81.0%, compared to 76.1% in 2022[15][16]. - Adjusted EBITDA for 2023 was HKD 99.4 million, up from HKD 66.1 million in 2022, indicating a significant improvement in operational efficiency[15]. - The company reported a pre-tax profit of HKD 75.9 million for 2023, a significant increase from HKD 43.3 million in 2022, marking a successful year of profitability[15]. - The net profit for 2023 was approximately HKD 70.9 million, showing a significant year-on-year increase of 84.04% due to strict cost control measures[36]. - The profit for the year hit a record high of approximately HKD 70.9 million, a significant increase of 84.04% year-on-year, with earnings per share rising to about HKD 1.11, up 82%[68]. - Sales of the flagship product, Jinyin Peptide®, generated approximately HKD 186.0 million, reflecting a 9.8% increase due to expanded hospital networks and digital sales channels[69]. - The revenue from the patented biopharmaceuticals segment was approximately HKD 226.9 million, a 9.2% increase, accounting for 46.8% of total sales[75]. - Other income increased by 57.8% to approximately HKD 13.6 million, driven by growth in the CMO business[82]. Product Development and Innovation - The company launched its fifth self-developed drug, Bo Gu Tai®, which received positive market response shortly after its release[22]. - The company has introduced a new product, a domestically produced pre-filled pen injection of teriparatide, which is expected to outperform existing imported products[22]. - The company launched Skbrella™ FN, a functional skincare ingredient that improves skin repair speed and tolerance, marking its entry into the medical aesthetics industry[24]. - The company is actively developing three additional functional skincare ingredients to diversify its product offerings and revenue sources[24]. - The company has developed two technical platforms, including a synthetic biology platform that could significantly reduce long-term production costs for bioparticles[26]. - The hydrogel technology platform focuses on creating temperature-sensitive hydrogel formulations for epidermal growth factor products, enhancing drug delivery and healing processes[26]. - The company has completed preliminary development of an anti-wrinkle peptide product, with plans for functional validation to follow[59]. - Collagen, which constitutes 25% to 35% of total body protein, is being developed for skincare applications, focusing on hydration and anti-aging[60]. - Microecological skincare products are being developed using synthetic biology techniques, with a project launched in collaboration with the Hong Kong Institute of Nano and Advanced Materials[61]. - Exosomes derived from mesenchymal stem cells (MSCs) are being explored for their regenerative properties in skincare, promoting collagen synthesis and reducing scar formation[62]. Research and Development - Research and development expenses accounted for 7.3% of total revenue in 2023, down from 8.1% in 2022, reflecting improved cost management[15][16]. - The establishment of a new R&D center in Beijing aims to facilitate breakthroughs in product development[25]. - The company continues to focus on R&D in endocrine diseases, ophthalmology, and dermatology, with multiple patented biopharmaceuticals and high-value generics in various stages of development[43]. - The company has doubled its EGF product production capacity and plans to quadruple it by April 2024, enhancing production efficiency and reducing costs[92]. - The synthetic biology technology platform aims to improve the production performance of E. coli, significantly lowering the cost of bioactive peptides[93]. Market Strategy and Expansion - The company aims to expand its market share through strategic partnerships and innovative product offerings in the Chinese healthcare market[5][22]. - The company is preparing for the fourth clinical study of Bogu Tai®, focusing on fracture prevention and pain relief, to enhance its competitive edge[88]. - The market for osteoporosis-related medical expenses is expected to soar to RMB 132 billion by 2035 and RMB 163 billion by 2050, indicating substantial growth opportunities[86]. - The dry eye medication market is expected to exceed RMB 42 billion by 2030, with an impressive CAGR of 28.4%[89]. - The Chinese functional skincare market is projected to reach RMB 122.4 billion by 2028, with a compound annual growth rate (CAGR) of 17.5% from 2023 to 2028[85]. Corporate Governance - The company is committed to maintaining high standards of corporate governance and transparency in its operations[118]. - The board includes independent directors with significant experience in finance and management, ensuring robust governance practices[118][119]. - The company has established procedures for handling and disseminating inside information, adopting a disclosure policy for compliance[166]. - The risk management process includes identifying, assessing, and managing risks that may affect the company's business and operations[163][164]. - The board conducts an annual review of the effectiveness of the risk management and internal control systems through the audit committee[165]. - The company has adopted all applicable corporate governance codes as per the listing rules, demonstrating its commitment to transparency and accountability[125]. Management and Leadership - The company has a strong management team with members holding advanced degrees from prestigious institutions, including Imperial College London and Peking University[113][114]. - The management team has received multiple industry awards, highlighting their leadership and innovation in the biotechnology sector[113]. - The company has appointed Mr. Du Kai as the Chief Financial Officer effective March 31, 2022, bringing over 18 years of financial and tax experience, particularly in the biopharmaceutical industry[122]. - The management team includes experienced professionals with extensive backgrounds in sales, manufacturing, R&D, and clinical research, contributing to the company's strategic goals[121]. - The board consists of seven members, including three executive directors and three independent non-executive directors, ensuring a balanced governance structure[126]. Shareholder Communication - The company maintains effective communication with shareholders through regular financial disclosures and updates on its website[178]. - The company emphasizes the importance of timely and balanced information dissemination to shareholders and potential investors[177]. - The company has audited its shareholder communication policy for the year ending December 31, 2023, and found it to be effectively implemented[181]. - Shareholders have the right to request special meetings if they hold at least 10% of the company's paid-up capital[173]. Future Outlook - The company is focused on expanding its market presence and enhancing its product offerings through strategic partnerships and acquisitions[117]. - The company is committed to enhancing shareholder value through prudent management and strategic decision-making[125].

Financial Performance - The company reported a basic and diluted earnings per share of HKD 35,340,000 for the year ended December 31, 2023, compared to HKD 36,479,000 for the previous year, reflecting a decrease of approximately 3.1%[23] - For the fiscal year ending December 31, 2023, the company's revenue reached approximately HKD 484.7 million, representing a year-on-year growth of 10.1%[33] - The profit for the year amounted to approximately HKD 70.9 million, showing a significant year-on-year increase of 84.04%, marking an important milestone for the research-based biopharmaceutical company[33] - The company achieved a record revenue of approximately HKD 484.7 million for the year ended December 31, 2023, representing a year-on-year growth of 10.1%[49] - Net profit for the year reached approximately HKD 70.9 million, a significant year-on-year increase of 84.04%, attributed to strict cost control measures[49] - Gross profit amounted to approximately HKD 392.8 million, an increase of 17.3% compared to approximately HKD 334.9 million in the previous year, with a gross margin improvement of 4.9 percentage points to 81.0%[125] - Basic earnings per share for 2023 was HKD 1.11, up from HKD 0.61 in 2022, indicating a growth of 81.0%[185] Expenses and Cost Management - The company recognized a total of HKD 1,755,000 in expenses related to auditor remuneration for the year, compared to HKD 1,816,000 in the previous year, indicating a slight decrease of about 3.4%[3] - Research and development expenses capitalized amounted to HKD 51,950,000, down from HKD 53,940,000 in the previous year, a decrease of approximately 3.7%[3] - General and administrative expenses as a percentage of revenue decreased from 10.7% to 9.8%, attributed to the company's ongoing internal control and cost-cutting measures[36] - Research and development expenses as a percentage of revenue decreased to 7.3% in 2023 from 8.1% in 2022[55] - Research and development expenses for the year were HKD 35,576,000, slightly down from HKD 35,781,000 in 2022[185] Revenue Sources and Growth - The total revenue from service income primarily related to entrusted processing business was not specified but is a key focus area for the company[2] - Sales of Pipanpu® and Jinyin Peptide® performed exceptionally well, growing by 15.0% and 9.54% year-on-year, respectively[33] - The flagship product, Jindan Peptide®, generated revenue of approximately HKD 186.0 million, reflecting a year-on-year increase of 9.8%[118] - The revenue from the chemical pharmaceuticals segment was approximately HKD 257.9 million, reflecting a year-on-year increase of 10.9%[124] - The patented biopharmaceuticals segment recorded sales of approximately HKD 226.9 million, a growth of about 9.2% year-on-year, accounting for 46.8% of total sales[123] Assets and Liabilities - The total assets of the group as of December 31, 2023, are approximately HKD 409.99 million, with current assets at about HKD 238.1 million[145] - The group's current liabilities as of December 31, 2023, amount to HKD 114.79 million, resulting in a current liabilities to total assets ratio of 28.0%[145] - Non-current liabilities increased significantly to HKD 38,028 thousand from HKD 7,470 thousand year-over-year[199] - Bank borrowings rose sharply to HKD 30,612 thousand compared to HKD 985 thousand in the previous year[199] - Total equity increased to HKD 257,174 thousand from HKD 194,746 thousand, reflecting a growth of approximately 32%[199] Corporate Governance and Compliance - The company has not declared or proposed any dividends for the year 2023, consistent with the previous year[21] - The board does not recommend the payment of a final dividend for the year ending December 31, 2023, consistent with the previous year[162] - The audit committee consists of three independent non-executive directors and has reviewed the consolidated financial statements for the year ending December 31, 2023[163] - The company has maintained compliance with the corporate governance code applicable as of December 31, 2023[164] Research and Development Initiatives - A new research and development center for green peptide innovative drugs and advanced technologies was established in Beijing, integrating the latest advancements in biological informatics, genetic engineering, and oral formulation technology[36] - The development of oral Uni-GLP-1 has shown superior bioavailability compared to the positive control oral semaglutide, with ongoing preparations for formal animal studies[68] - UB101, a dual-target nanobody, is being developed to treat wet age-related macular degeneration, aiming to overcome the limitations of intravitreal injections[69] - The company is focusing on innovative and patented products in endocrinology, ophthalmology, and dermatology, with multiple leading patented biopharmaceuticals in different stages of development[84] - The group is at the forefront of developing a new temperature-sensitive hydrogel formulation for EGF products, which enhances drug delivery and accelerates wound healing[152] Market Opportunities and Strategic Developments - The company is actively exploring commercialization opportunities for Skbrella™ FN to unlock its full market potential[61] - The market for osteoporosis-related medical expenses is projected to soar to RMB 132 billion by 2035 and RMB 163 billion by 2050, indicating substantial growth potential for Bogu Tai®[134] - The dry eye medication market is anticipated to exceed RMB 42 billion by 2030, with a remarkable CAGR of 28.4%, presenting a significant growth opportunity for the company[137] - The Chinese functional skincare market is projected to reach RMB 122.4 billion by 2028, with a compound annual growth rate of 17.5% from 2023 to 2028[150] Share Repurchase and Investments - The company repurchased 86,000,000 shares at a total cost of HKD 5.167 million, with the highest price per share being HKD 0.069 and the lowest HKD 0.052[29] - A total of 86,000,000 shares were repurchased during the year ending December 31, 2023, with an additional 115,180,000 shares repurchased in January 2024[174] - The company provided a loan of RMB 7.15 million to Guangzhou Taili Biological Pharmaceutical Technology Co., Ltd. for a term of 24 months starting September 19, 2023[179] Legal and Regulatory Matters - The company has not been involved in any significant legal proceedings or arbitration as of December 31, 2023[12] - The sodium diquafosol eye drops application was officially accepted by the drug regulatory authority in January 2024, with expectations for market approval in Q1 2025[95] - The completion of the sale of shares in Huashengyuan is subject to additional time due to new government regulations[181]

Financial Performance - For the first half of 2023, the company's revenue increased significantly by 27.8% year-on-year to approximately HKD 249.9 million, while profit surged by 169.2% to about HKD 39.4 million[14]. - The gross profit for the first half of 2023 was HKD 198.9 million, reflecting a 37.6% increase compared to HKD 144.5 million in the same period last year[26]. - Operating profit rose by 35.0% to HKD 54.7 million, up from HKD 40.5 million in the previous year[26]. - The total comprehensive income for the period was HKD 30.0 million, compared to HKD 6.2 million in the previous year[121]. - Basic and diluted earnings per share were HKD 0.62, up from HKD 0.23 in the same period last year[121]. - The company reported a pre-tax profit of HKD 43,395,000 for the first half of 2023[185]. - The income tax expense for the first half of 2023 was HKD 3,994,000, significantly higher than HKD 650,000 in the previous year[192]. Research and Development - Research and development costs decreased by 51.7% to HKD 11.7 million, compared to HKD 24.3 million in the prior year[26]. - The company is conducting animal studies to further validate the bioavailability of its oral Uni-GLP-1 formulation, which has shown superior efficacy compared to the positive control[41]. - The company is developing innovative technologies to overcome the limitations of current treatments for wet age-related macular degeneration[41]. - The company is focused on biotechnology, particularly in developing and commercializing biological drugs through DNA and other technological research[200]. - Research and development expenses amounted to HKD 23,025,000, slightly down from HKD 24,316,000 in the previous year[189]. Product Development and Launches - The company successfully launched its first advanced skincare raw material product, a recombinant human fibronectin protein, in May 2023, aimed at various skin conditions[15]. - The company is preparing for the launch of its product "Bogu Tai" in the second half of 2023 after completing necessary regulatory approvals[30]. - The second-generation Uni-PTH injection pen, named Bogu Tai, is expected to be approved for market launch in 2023, enhancing patient convenience and safety[63]. - The company is actively exploring commercialization opportunities for the recombinant protein to maximize its market potential[15]. - The company is leveraging synthetic biology to develop a range of new skincare ingredients, including collagen and beauty peptides, for commercialization[45]. Market Trends - The global wound dressing market is expected to reach $24.01 billion by 2028, with a compound annual growth rate (CAGR) of 6.1% from 2021 to 2028[44]. - The Chinese wound dressing market grew from RMB 5.52 billion in 2014 to RMB 13.62 billion in 2018, representing a CAGR of 25.3%[44]. - The Chinese wound dressing market is projected to reach RMB 23.45 billion in 2023, maintaining a CAGR of 11.1% from 2019 to 2023[44]. - The skincare market is experiencing significant growth, with the Chinese beauty medical market expected to exceed RMB 200 billion in 2023, driven by post-pandemic recovery and rising disposable income[55]. - The healthcare market in China is expected to maintain strong growth, with a projected compound annual growth rate of 8.8% from 2023 to 2027, reaching USD 26.8 billion by 2027[103]. Financial Stability and Investments - As of June 30, 2023, the company's cash and bank balances were approximately HKD 95.3 million, with total assets of approximately HKD 311.3 million, up from HKD 292.5 million at the end of 2022[133]. - The total liabilities to total assets ratio as of June 30, 2023, was 25.8%, down from 30.9% at the end of 2022, indicating improved financial stability[133]. - The total equity as of June 30, 2023, is HKD 224,759,000, an increase from HKD 194,746,000 as of December 31, 2022, representing a growth of approximately 15.4%[167]. - The net cash generated from operating activities for the six months ended June 30, 2023, is HKD 30,360,000, compared to HKD 9,547,000 for the same period in 2022, indicating a significant increase of 218.5%[169]. - The company did not engage in any significant investments or plans for major capital assets during the six months ended June 30, 2023[134]. Marketing and Sales - A comprehensive marketing strategy has been developed to ensure the successful market entry of Bogu Tai, including a national press conference planned for Q4 2023 to create significant impact[130]. - The company has established a dedicated marketing department to cover all digital channels, reflecting its commitment to maintaining a leading position in the evolving healthcare sector[131]. - The flagship product, Jin Yin Peptide, generated revenue of approximately HKD 95.9 million, an increase of 31.8% year-on-year, due to the expansion of the hospital network and upgraded production capacity[87]. - The sales of patented biopharmaceuticals reached approximately HKD 118.2 million, a substantial increase of 30.6% compared to the same period last year, accounting for 47.3% of total sales[90]. - The revenue from the chemical pharmaceuticals segment reached approximately HKD 131.8 million, a significant increase of 25.4% compared to the same period last year[91].

Financial Performance - Revenue for the year ended December 31, 2022, was HKD 440.316 million, representing a 24.6% increase from HKD 353.405 million in 2021[13]. - Gross profit for the same period was HKD 334.883 million, with a gross margin of 76.1%, down from 78.4% in the previous year[13][18]. - The company achieved a historical revenue high in 2022, with a year-on-year increase of 24.6% despite challenges from the COVID-19 pandemic[39]. - The company recorded a record revenue of approximately HKD 440.3 million for the year 2022, representing a significant year-on-year growth of 24.6% from HKD 353.4 million in 2021[69]. - The company achieved a net profit of approximately HKD 38.5 million in 2022, a substantial increase of 296.6% compared to a loss of HKD 19.6 million in 2021[70]. - The sales cost increased by 38.0% to approximately HKD 105.4 million in 2022, up from about HKD 76.4 million in 2021, while gross profit rose by 20.9% to approximately HKD 334.9 million[69]. - The gross margin for 2022 was 76.1%, slightly down from 78.4% in 2021[69]. Research and Development - Research and development expenses were HKD 35.781 million, accounting for 8.1% of revenue, a decrease from 14.2% in 2021[13][19]. - The company is focusing on R&D in endocrine diseases, ophthalmology, and dermatology, with multiple patented biopharmaceuticals and high-value generic drugs at various stages of development[44]. - The company is committed to enhancing its R&D capabilities and has partnered with Oran Biomedicine and DotBio to explore new applications for cell-penetrating protein technology[96]. - The company is researching oral delivery innovations for peptide drugs, with the third-generation Uni-PTH product showing promise in enhancing competitiveness in the endocrine field[97]. - The company is developing new products such as sodium diquafosol eye drops, which are expected to provide a new clinical treatment option for dry eye patients in China[91]. Product Development and Market Strategy - The company has two new prescription drugs, Uni-E4 and Uni-PTH, that have completed clinical trials, targeting type 2 diabetes and osteoporosis respectively[10][11]. - The company launched a new product, 博固泰®, expected to receive market approval by September 2023, marking its fifth self-developed drug[26]. - The new drug application for Bogutai® (teriparatide injection) was accepted by the National Medical Products Administration, preparing for entry into the osteoporosis market[41]. - The company is preparing for a national centralized procurement for Pinapu® in April 2023, aiming to secure its position in future procurements[27]. - The product BoguTai® is anticipated to receive market approval by September 2023, aiming to capture a significant share of the projected $81.5 billion osteoporosis market in China by 2031[92]. Market Performance - The company successfully captured nearly 50% market share for its product, Pinapu®, significantly outperforming competitors in sales[27]. - The flagship product, Jin Yin Peptide®, generated revenue of approximately HKD 169.4 million in 2022, a slight decline of 0.6% from HKD 170.5 million in 2021[72]. - The proprietary biological drugs generated sales of approximately HKD 207.8 million, a growth of 0.5% compared to the previous year, accounting for 47.2% of total sales[78]. - The proprietary chemical drugs, including Pinafu® and Boshu Tai®, achieved revenue of approximately HKD 232.5 million, a substantial increase of 58.5% year-on-year[79]. Corporate Governance - The board consists of seven members, including three executive directors and three independent non-executive directors, ensuring a balanced governance structure[139]. - The company has adopted all applicable corporate governance codes as per the listing rules, demonstrating its commitment to transparency and accountability[138]. - The independent non-executive directors are confirmed to meet independence criteria, ensuring unbiased judgment in strategic decisions[141]. - The company emphasizes maintaining and improving corporate governance quality to enhance investor confidence and ensure stable growth[137]. - The board is responsible for determining the company's corporate governance policies and ensuring compliance with legal and regulatory requirements[170]. Financial Health and Ratios - The cash ratio improved to 1.09 from 0.91, and the current ratio increased to 2.22 from 2.18[15]. - The debt-to-equity ratio decreased to 50.2% from 53.5%[15]. - Total asset turnover improved to 150.6% from 132.1%[15]. - As of December 31, 2022, the company's cash and bank balances were approximately HKD 98.22 million, with total assets of approximately HKD 292.47 million[99]. - The company's current liabilities as of December 31, 2022, were approximately HKD 90.26 million, resulting in a current liabilities to total assets ratio of 30.9%[99]. Management and Leadership - The company has a strong management team with members holding advanced degrees from prestigious institutions, including Peking University and the University of Hartford[126][127]. - The management team has a combined experience of over 100 years in various sectors, including finance, consulting, and corporate governance[128][130]. - The company appointed Mr. Liang Guolong as Executive Director and Chairman of the Board since January 13, 2017, with extensive experience in investment banking and biotechnology[122]. - Mr. Zhao Zhigang has been the CEO since April 8, 2019, and has over 20 years of experience in corporate finance and auditing, previously serving as CFO for several listed companies[124]. - The company has appointed Mr. Du Kai as the Chief Financial Officer, effective March 31, 2022, bringing over 17 years of financial and tax experience, particularly in the biopharmaceutical industry[132]. Employee and Talent Management - The company employed 370 staff members as of December 31, 2022, with a focus on competitive compensation to attract and retain talent[101]. - The company has achieved gender diversity among employees, with a male-to-female ratio improving from 70:100 last year to 100:100[181]. - The board currently consists entirely of male members, but the company aims to appoint female directors to meet diversity requirements by December 31, 2024, targeting a female representation of over 10%[180]. Compliance and Ethics - The company emphasizes high standards of business ethics and integrity, requiring all employees to adhere to a long-established code of conduct[198]. - The group has established business codes for all manufacturers and suppliers, ensuring safe and healthy workplaces and fair recruitment practices[198]. - The company closely monitors compliance with the codes of conduct set by major licensors and customers for its manufacturers and suppliers[198]. Future Outlook - The company anticipates that the pharmaceutical and healthcare industry in China will continue to thrive due to aging population, domestic substitution, and supportive policies[87]. - The company plans to continue focusing on gender diversity among employees to enhance its future competitiveness[181]. - The company is committed to ongoing research and development of new products and technologies to drive future growth[130].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈之內容 概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示概不就 因本公佈全部或任何部分內容而產生或因倚賴該等內容而引致之任何損 失承擔任何責任。 UNI-BIO SCIENCE GROUP LIMITED 聯 康 生 物 科 技 集 團 有 限 公 司* （於開曼群島註冊成立之有限公司） （股份代號：0690） 截 至 二 零 二 二 年 十 二 月 三 十 一 日 止 年 度 之 末 期 業 績 公 佈 截至二零二二年十二月三十一日止年度摘要 • 截至二零二二年十二月三十一日止年度（「年內」），本集團營業額創 新高，達到440.3百萬港元，按年（「按年」）顯著增長24.6%。 • 年 內，本 集 團 扭 虧 為 盈，盈 利38.5百 萬 港 元，按 年 大 幅 增 長296.6%， 成為一家研究型生物製藥公司的重要里程碑。 • 匹 納 普®及 及 博 舒 泰®的 銷 售 表 現 異 常 出 色，按 年 分 別 增 長51.2%及 292.5%。 ...

Financial Performance - For the six months ended June 30, 2022, the company reported revenue of HKD 195,578,000, representing a year-on-year increase of 24.6% from HKD 156,984,000[9]. - Gross profit for the same period was HKD 144,507,000, with a gross margin of 73.9%, down from 79.3% in the previous year[9]. - The company achieved a significant increase in profit before tax, reaching HKD 15,289,000, a 429% rise compared to HKD 2,890,000 in the prior year[12]. - The company achieved a net profit of approximately HKD 14.6 million, a substantial increase of 663.6% compared to HKD 1.9 million in the first half of 2021[59]. - The gross margin for the first half of 2022 was 73.9%, down from 79.3% in the same period of 2021[58]. - The company reported a total comprehensive income for the period of HKD 6,226,000, compared to HKD 4,168,000 in the previous year, indicating a growth of 49.4%[118]. - The company reported a loss of HKD 2,008,161,000 as of June 30, 2022, which reflects a slight decrease from the previous year's loss of HKD 2,010,078,000[128]. Research and Development - Research and development expenses amounted to HKD 24,316,000, accounting for 12.4% of total revenue, a slight decrease from 13.6% in the previous year[9]. - The company is focusing on R&D in endocrine diseases, ophthalmology, and dermatology, with multiple patented biopharmaceuticals and high-value generics in various stages of development[26]. - The company’s R&D expenses grew by 13.8% to approximately HKD 24.3 million, reflecting its commitment to innovation and development[58]. - The company is committed to developing a third-generation oral Uni-PTH, which currently has no market equivalents, enhancing its competitive edge in the endocrine field[92]. - The company is preparing to develop an oral GLP-1 formulation, which has shown superior effects in animal tests compared to existing products on the market[92]. Product Development and Market Expansion - The company launched four products in the market, including Jinyin Peptide® and Boshutai®, enhancing its product portfolio[16]. - The company successfully won procurement bids for "Boshutai" (Acarbose Tablets) in 13 provinces in China, providing an opportunity to rapidly expand its hospital market share[25]. - The company is expanding its Suzhou production capacity to meet the anticipated high demand for "Boshutai" and is preparing to develop Diquafosol Sodium Eye Drops as part of its high-value generics strategy[25]. - The anticipated launch of Bogu Tai (Teriparatide injection) is expected to provide better drug options for patients and tap into the growing osteoporosis market, projected to grow from USD 21.2 billion in 2021 to USD 81.5 billion by 2031[85]. - The company is exploring various ophthalmic products to fully utilize the capacity of the new BFS production line, including a high-value generic eye drop for dry eye syndrome, leveraging API cost advantages[89]. Market Outlook - The Chinese pharmaceutical market is projected to reach RMB 1.868 trillion by 2022, indicating strong growth potential for the company[15]. - The global wound dressing market is expected to reach $24.01 billion by 2028, with a compound annual growth rate (CAGR) of 6.1% from 2021 to 2028[41]. - The Chinese wound dressing market has grown from RMB 5.52 billion in 2014 to RMB 13.62 billion in 2018, with a CAGR of 25.3%, and is projected to maintain an 11.1% CAGR, reaching RMB 23.45 billion by 2023[41]. - The company is optimistic about the prospects of the Chinese pharmaceutical and medical aesthetics markets, which are expected to create significant value for established enterprises[15]. Financial Position and Liquidity - The company maintained a cash ratio of 1.07 and a current ratio of 2.62, indicating improved liquidity compared to 0.91 and 2.18, respectively, in the previous year[9]. - As of June 30, 2022, the company's cash and bank deposits amounted to approximately HKD 81.33 million, with total assets of about HKD 262.48 million[93]. - The company's total liabilities to total assets ratio decreased to 31.2% as of June 30, 2022, down from 34.9% at the end of 2021[93]. Corporate Strategy - The company plans to upgrade its business model to a "four-wheel drive" model focusing on high-value generics, biological innovations, new skincare raw materials, and CMO business[79]. - The company is collaborating with a cosmetics partner to develop competitive skincare raw materials, aiming for commercialization in the first half of 2023[83]. - The company is leveraging its research ecosystem and bioprocessing platform to rapidly commercialize new skincare products, including collagen and stem cell exosome products[43]. Employee and Operational Insights - The company employs 340 staff members, including 32 in R&D, 170 in production, and 78 in commercial offices in China, with competitive compensation to attract and retain talent[105]. - The company has issued 6,364,768,147 shares as of June 30, 2022, with a total capital of HKD 63,648,000[183].

Financial Performance - Uni-Bio Science Group reported a revenue of HKD 353.4 million for the year ended December 31, 2021, compared to HKD 208.8 million in 2020, representing an increase of 69.2%[7]. - The gross profit for the same period was HKD 277.0 million, with a gross margin of 78.4%[7]. - The company's revenue reached a record high in 2021, showing a significant year-on-year growth of 69.3%, driven by strong sales of core products[28]. - The sales of the proprietary biological drugs, including Jinyin Peptide® and Jinyin Shu®, amounted to HKD 206.7 million, an increase of approximately 22.7% year-on-year, accounting for about 58.5% of total sales[56]. - The sales of the proprietary chemical drug, Pinap® (Voriconazole tablets), recorded significant growth, with revenue increasing from approximately HKD 37.5 million to about HKD 142.2 million due to inclusion in the national centralized procurement[53]. - The gross profit for the year was approximately HKD 277.0 million, a 53.0% increase from about HKD 181.1 million in 2020, although the gross margin decreased to 78.4% from 86.7% due to pricing discounts from centralized procurement[59]. - The company reported an operating loss of HKD 20.0 million for the year, a substantial reduction from a loss of HKD 70.9 million in 2020[49]. - The total loss narrowed to HKD 19.6 million compared to HKD 71.3 million in 2020[66]. Research and Development - Research and development expenses accounted for 14.2% of total revenue, amounting to HKD 50.2 million[7]. - The company is focusing on R&D in endocrine diseases, ophthalmology, and dermatology, with multiple patented biopharmaceuticals in various stages of development[33]. - The company has several leading patented biopharmaceuticals and high-quality generic drugs currently in different research and development phases[34]. - The second-generation Uni-PTH (pre-filled injection pen) has successfully completed clinical trials and is expected to submit a new drug application in 2022[36]. - The oral GLP-1 product under development has shown to be twice as effective as the clinical efficacy of the overseas oral GLP-1 product, semaglutide, in pharmacokinetic studies on mice[39]. - The company has initiated clinical work for the Uni-GLP-1 water injection and plans to accelerate further clinical work in 2022[37]. - The company is developing a third-generation oral Uni-PTH and collecting data for its development[36]. - The company has completed clinical trials for Uni-PTH and plans to submit a new drug application in 2022, while Uni-GLP-1's preliminary trials are expected to finish by the end of 2022[74]. Market Expansion and Strategy - Uni-Bio Science aims to enhance its operational excellence and expand its market presence in the Chinese healthcare sector[3]. - The company is committed to improving patient quality of life through innovative treatments[5]. - Uni-Bio Science is focused on becoming a leading biopharmaceutical company by introducing high-quality medical solutions to Chinese patients[3]. - The company is expanding into the medical aesthetics and functional skincare markets, with new products expected to launch within the next two years[17]. - The collaboration with Global Cosmetic aims to develop competitive new skincare raw materials[14]. - The company is optimizing production scale and efficiency for its generic drugs, particularly PinaP, to meet increasing public hospital orders[18]. - A partnership with National Pharmaceutical Group and Suzhou Yingli will enhance the supply chain and production capacity for BoShuTai[18]. - The company is exploring innovative technologies with multiple biological companies to provide alternative treatments for wet age-related macular degeneration[40]. Corporate Governance - The board consists of seven members, including three executive directors and three independent non-executive directors, ensuring a balanced governance structure[116]. - The responsibilities of the Chairman and CEO are clearly separated, enhancing accountability and independence[114]. - The audit committee consists of three independent non-executive directors and has reviewed the audited consolidated financial statements for the year ending December 31, 2021[82]. - The company has adopted the standard code of conduct for securities trading as per the listing rules, confirming compliance by all directors[84]. - The company aims to maintain and improve corporate governance quality to enhance investor confidence and support stable growth[112]. - The company has established a policy for appointing external auditors and reviewing their independence and objectivity[134]. - The board has established a process for identifying, assessing, and managing risks, ensuring continuous monitoring and reporting[156]. - The company maintains effective communication with shareholders, providing opportunities for direct interaction during the annual general meeting[161]. Production and Facilities - The company operates two GMP-certified production facilities located in Beijing and Shenzhen[6]. - A new production facility in Dongguan is set to begin construction in April 2022, aiming to enhance production efficiency and reduce costs by 2025[15]. - The new production base in Dongguan is expected to be operational by 2025, aimed at increasing production capacity and reducing costs[76]. Shareholder Information - The total number of issued shares as of December 31, 2021, is 6,349,768,147[198]. - Liang Guolong holds 1,846,832,542 shares, representing approximately 29.44% of total shares[192]. - Qiu Guorong holds 865,040,000 shares, representing approximately 13.72% of total shares[192]. - The total shares held by directors and their related entities amount to 2,740,000,000 shares[192]. - The percentage of shares held by the top five shareholders is approximately 47.85%[192]. Future Outlook - The Chinese pharmaceutical market is expected to reach USD 300.9 billion by 2025, with a compound annual growth rate (CAGR) of 12.2% driven by aging population and regulatory reforms[67]. - The global functional cosmetics market is projected to reach USD 4.1 billion by 2026, growing at a compound annual growth rate of 5.2% from USD 3.2 billion in 2021[25]. - The functional skincare market in China reached RMB 26.01 billion in 2021 and is projected to grow at a CAGR of 29.4%, reaching RMB 58.97 billion by 2023[69].

Financial Performance - Revenue for the six months ended June 30, 2021, reached HKD 156.98 million, a significant increase of 132.8% compared to HKD 67.43 million in the same period of 2020[7]. - Gross profit for the same period was HKD 124.44 million, representing a 117.1% increase from HKD 57.31 million year-on-year[7]. - The company achieved a profit before tax of HKD 2.89 million, recovering from a loss of HKD 11.05 million in the previous year[9]. - The group reported a profit of HKD 1.9 million for the first half of 2021, a turnaround from a loss of HKD 11.5 million in the same period of 2020, marking the first operational profit in a half-year period[58]. - The operating profit for the first half of 2021 was HKD 3.16 million, a significant improvement from an operating loss of HKD 10.78 million in the previous year[77]. - The group reported a pre-tax profit of 2,890 thousand HKD for the six months ended June 30, 2021, compared to a pre-tax loss of 11,053 thousand HKD for the same period in 2020[101][103]. Research and Development - Research and development expenses increased to HKD 21.37 million, accounting for 13.6% of revenue, compared to 22.7% in the previous year[7]. - The company is focusing on R&D in endocrine diseases, ophthalmology, and dermatology, with multiple patented biopharmaceuticals and high-quality generics in various stages of development[17]. - The patented biopharmaceutical Uni-PTH is designed to effectively treat osteoporosis and bone pain, with clinical trials for the second generation expected to start in August 2021[32]. - The GLP-1 product is the world's first fully biologically expressed GLP-1 formulation, expected to become a leading diabetes product in China due to its clinical and cost advantages[33]. - The company is preparing for clinical trials of Uni-GLP, anticipated to begin in Q3 2021, with potential to bypass Phase III trials if results are favorable[33]. - The company is developing UB101 and UB102, dual-specific nanobodies for treating wet AMD, with clinical trials planned for November 2021[36]. Market and Product Development - The company launched four products in the market, including JinYinPeptide® and JinYinShu®, contributing to significant sales growth[12]. - The Chinese pharmaceutical market is projected to grow to RMB 222.88 billion by 2024, with a compound annual growth rate of 6.4% from 2019 to 2024, indicating a favorable market environment for the company[11]. - The company plans to continue expanding its product offerings and market presence in response to the growing demand in the pharmaceutical sector[11]. - PinaP® (Voriconazole Tablets) has been included in the fourth batch of national centralized procurement, which will enhance its market penetration in public hospitals, the main sales channel[15]. - Sales of the flagship product, Jinyin Peptide®, reached HKD 82.4 million, a 116.8% increase from approximately HKD 38 million in the first half of 2020[43]. - Sales of the chemical drug, Pinabup® (Voriconazole Tablets), surged by 257.3% to approximately HKD 56.1 million, driven by its inclusion in the national centralized procurement[46]. Financial Position and Liquidity - The cash ratio improved to 1.09 times, up from 0.4 times in the previous year, indicating better liquidity management[7]. - As of June 30, 2021, the company's cash and cash equivalents were approximately HKD 97.23 million, with total assets of HKD 287.75 million[66]. - The total liabilities to total assets ratio increased to 32.4% as of June 30, 2021, compared to 25.1% at the end of 2020[66]. - The company's equity increased to HKD 194,582 million in June 2021 from HKD 189,411 million in December 2020, indicating a solid capital position[83]. - The company reported a significant increase in cash flow, with a net increase of HKD 69,967 million in cash and cash equivalents during the first half of 2021[86]. Shareholder Information - The average number of ordinary shares for calculating basic and diluted earnings per share was 6,396,892 thousand shares for the six months ended June 30, 2021[116]. - The total beneficial ownership of the directors includes 1,869,611,542 shares, which is 29.19% of the total issued shares[156]. - The company has granted stock options involving 563,055,000 shares as of June 30, 2021, representing 8.79% of the issued ordinary shares[138]. - The company reported a basic and diluted profit attributable to shareholders of 1,917 thousand HKD for the six months ended June 30, 2021, compared to a loss of 11,458 thousand HKD for the same period in 2020[116]. - The company did not recommend any interim dividend for the six months ended June 30, 2021[74]. Corporate Governance - The company confirmed compliance with the corporate governance code during the reporting period[163]. - The board of directors has adopted the standard code for securities transactions, ensuring adherence throughout the reporting period[164]. - The mid-term report, including a concise consolidated financial statement, was reviewed by the company's audit committee[165].

Financial Performance - Total revenue for the year ended December 31, 2020, was HKD 208,776,000, with a gross profit of HKD 181,094,000, resulting in a gross margin of 86.7%[11] - The group’s revenue for the year ended December 31, 2020, was approximately HKD 208.8 million, a slight decrease of about 0.3% compared to HKD 209.4 million in 2019[52] - Gross profit for the year was HKD 181.1 million, maintaining a stable gross margin of 86.7%[52] - Operating loss for the year was HKD 70.9 million, with normalized operating loss decreasing significantly from HKD 62.7 million in 2019 to HKD 34.8 million in 2020[53] - Sales of the flagship product, Jinyin Peptide®, generated revenue of HKD 137.2 million, an increase of 9.5% from approximately HKD 125.3 million in 2019[54] - Sales of the patented biological drugs amounted to HKD 168.5 million, representing a growth of approximately 6.4% and accounting for about 80.7% of total sales[61] - The revenue from the chemical drugs segment was HKD 40.3 million, with sales from Pinab® and Bokangtai® generating HKD 37.5 million and HKD 2.8 million, respectively[62] - The company recorded a loss of HKD 71.3 million for the year, compared to a profit of HKD 2.5 million in 2019[69] Research and Development - Research and development expenses amounted to HKD 40,728,000, representing 19.5% of total revenue[12] - The company is focused on the development of innovative drugs, including Uni-GLP and Uni-PTH, with clinical trial applications approved for Uni-GLP and Uni-PTH in 2020[78] - The company has received approval for clinical trial applications for GLP-1 injection and Uni-PTH, indicating progress in its product development pipeline[31] - The clinical trial application for Uni-GLP was accepted by the drug regulatory authority on July 14, 2020, indicating progress in product development[45] - The company continues to focus on R&D in ophthalmic, dermatological, and endocrine diseases, with multiple patented biopharmaceuticals in various stages of development[39] Market Opportunities - The Chinese biopharmaceutical market is projected to grow at a compound annual growth rate (CAGR) of 17.5% from 2019 to 2025, reaching RMB 833.2 billion by 2025, presenting new opportunities for the company[18] - The global pharmaceutical market is projected to reach USD 2,151.1 billion by 2027, with a compound annual growth rate (CAGR) of 7.0% from 2019 to 2027[70] - The prevalence of wet age-related macular degeneration is projected to increase from 3.4 million in 2017 to 4.8 million by 2030, indicating a growing market for the company's new therapies[79] Strategic Initiatives - The AGILE five-year plan focuses on promoting growth and international expansion[3] - The company aims to enhance its operational foundation to support strong growth prospects in the future[4] - The company aims to create a leading drug commercialization platform in China by seeking collaborations with innovative research and technology firms to enrich its product portfolio[19] - The company is actively investing in electronic business channels, with the online healthcare market expected to provide better products and services to patients, thereby boosting product sales and brand awareness in the coming years[29] - A strategic partnership was formed in May 2020 to expand the electronic promotion channels and internet pharmaceutical platforms, enhancing service quality for patients and healthcare professionals[38] Operational Efficiency - The company has established strategic partnerships with specific distributors and hospitals to enhance operational efficiency and reduce general and administrative expenses, which have decreased for three consecutive years[18] - The company has seen a 39.7% reduction in general and administrative expenses, down to HKD 35.8 million, which is about 17.2% of revenue compared to 28.4% in 2019[52] - Sales and distribution expenses decreased from HKD 149.3 million in 2019 to HKD 145.5 million in 2020, with the percentage of sales expenses to revenue dropping from 71.3% to 70%[64] Corporate Governance - The company emphasizes good corporate governance practices to enhance investor confidence and ensure stable growth[119] - The board of directors consists of seven members, including three executive directors and three independent non-executive directors, ensuring a balanced governance structure[122] - The management team meets monthly to review business performance and coordinate resources, demonstrating a commitment to operational efficiency[126] - The company has a clear division of responsibilities between the chairman and the CEO, enhancing accountability and independence[121] - The board held regular meetings to review overall strategy and monitor financial performance, with management providing relevant reports prior to each meeting[128] Liquidity and Financial Position - The cash ratio was 0.4, and the current ratio was 3.01, indicating strong liquidity positions[11] - As of December 31, 2020, the company's cash and cash equivalents amounted to approximately HKD 25 million, with total assets of approximately HKD 252.7 million[84] - The company's current liabilities increased to HKD 60.4 million as of December 31, 2020, compared to HKD 54.6 million in the previous year[84] Shareholder Relations - The company has maintained effective communication with shareholders, providing opportunities for direct interaction during the annual general meeting[170] - The company has adopted a dividend policy, with the board having full discretion to declare and recommend dividends subject to shareholder approval[167] - The board of directors did not recommend the payment of dividends for the year ended December 31, 2020[180] Human Resources - The company employed 293 staff as of December 31, 2020, with a focus on competitive compensation to attract and retain talent[85] - The number of senior management in the group for the year ended December 31, 2020, included 4 individuals earning between HKD 0 to 1,000,000 and 1 individual earning between HKD 3,000,001 to 3,500,000[147] Risk Management - The board is responsible for reviewing the effectiveness of the internal control system, which was deemed sufficient and effective[159] - The risk management process includes identifying risks that may affect the group's business and operations[160] - The board has conducted an annual review of the effectiveness of the group’s risk management and internal control systems[166]

Financial Performance - Revenue for the first half of 2020 was HKD 67,433,000, a decrease of 30.7% compared to HKD 97,313,000 in 2019[9] - Gross profit for the same period was HKD 57,314,000, down 29.1% from HKD 80,835,000 in 2019[9] - The company reported a loss before tax of HKD 11,053,000, a significant decline from a profit of HKD 45,387,000 in the previous year[11] - The company recorded a revenue of approximately HKD 67.4 million for the six months ended June 30, 2020, representing a year-on-year decline of about 30.7% from HKD 97.3 million in the same period of 2019[36] - The company reported a loss of HKD 11.5 million for the first half of 2020, compared to a profit of HKD 44.9 million in the same period of 2019, reflecting a significant narrowing of losses[41] - The company incurred an operating loss of HKD 10,782,000, compared to an operating profit of HKD 45,982,000 in the previous year[70] - The net loss for the period was HKD 11,458,000, compared to a profit of HKD 44,895,000 in 2019[70] - The total comprehensive loss for the period amounted to HKD 15,386,000, compared to a comprehensive income of HKD 47,642,000 in the previous year[70] Research and Development - R&D expenses amounted to HKD 15,323,000, representing 22.7% of revenue, compared to 21.9% in 2019[9] - The company is actively developing patented products in endocrine diseases, ophthalmology, and dermatology, focusing on new patented biopharmaceuticals and high-quality generics[21] - The Uni-PTH product is expected to receive registration approval in early 2021, with plans for a market launch shortly thereafter[23] - The Uni-GLP product, a fully biologically expressed GLP-1 formulation, is anticipated to enter the market by 2023, following successful clinical trial approvals[28] - The company is conducting feasibility studies for third-generation oral PTH and GLP-1 products, with plans to expand GLP-1 applications to obesity treatment[59] - Research and development expenses amounted to HKD 15,323,000 for the first half of 2020, down from HKD 21,269,000 in the same period of 2019, representing a decrease of approximately 28%[119] Cost Management - The company implemented cost control measures, resulting in a 35.2% reduction in general and administrative expenses to HKD 10.6 million[39] - General and administrative expenses decreased by 35.2% to HKD 19.6 million in the first half of 2020 from HKD 30.2 million in the same period of 2019, reflecting the effectiveness of the company's restructuring plan[51] - Sales and distribution expenses decreased by 41.6% to HKD 42,549,000 from HKD 72,891,000 in 2019[11] - Sales and distribution expenses decreased from approximately HKD 72.9 million in the first half of 2019 to about HKD 42.5 million in the first half of 2020, with the percentage of sales expenses to revenue dropping from 74.9% to 63%[48] Market and Product Development - The clinical trial application for Uni-GLP was approved by the National Medical Products Administration, with plans for two clinical trials in the next 18 months[15] - The company remains optimistic about the commercial value of the second-generation Uni-GLP, expected to launch by 2023[15] - The strategic partnership with National Pharmaceutical Group and Suzhou Yingli aims to enhance the supply chain for Acarbose tablets, ensuring at least ten years of stable supply for commercialization[17] - The collaboration with Swiss company Ypsomed focuses on developing new pre-filled injection pen products for diabetes and osteoporosis, with the potential to launch compatible GLP-1 and PTH formulations in China[18] - The company plans to launch Acarbose tablets within three to six months after production assessment completion, targeting pre-diabetic patients and those with postprandial hyperglycemia[57] Shareholder Information - The company did not recommend any interim dividend for the six months ended June 30, 2020[68] - The company repurchased a total of 18,640,000 shares for a total cash consideration of HKD 2,982,883 during the period from April 3, 2020, to May 11, 2020[66] - The total number of issued shares as of June 30, 2020, is 6,425,768,147[152] - The beneficial owner Chen Dawei holds 155,094,438 shares, which is 2.94% of the total issued shares[151] Compliance and Governance - The company has complied with the corporate governance code as per the listing rules during the reporting period[156] - All directors confirmed compliance with the standard code of conduct for securities transactions during the reporting period[157] - The mid-term report, including the condensed consolidated financial statements, was reviewed by the company's audit committee[158]